DSpace DSpace Softwareについて English
 

GINMU >
01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2018年度 >

このアイテムの引用には次の識別子を使用してください: http://hdl.handle.net/10564/3542

タイトル: Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study).
その他のタイトル: ダパグリフロジン投与における肥満2型糖尿病患者の治療満足度への影響:a patient reported outcome study (PRO study).
著者: Nakajima, Hiroki
Okada, Sadanori
Mohri, Takako
Kanda, Eiichiro
Inaba, Naoyuki
Hirasawa, Yoko
Seino, Hiroaki
Kuroda, Hisamoto
Hiyoshi, Toru
Niiya, Tetsuji
Ishii, Hitoshi
キーワード: Type 2 diabetes mellitus
Oral hypoglycemic agent
Sodium glucose cotransporters 2 inhibitors
SGLT2 inhibitors
Dapagliflozin
Treatment satisfaction
Oral Hypoglycemic Agent-Questionnaire
Body weight
Patient reported outcome
Quality of life
発行日: 2018年3月1日
出版者: BioMed Central
引用: Diabetology and metabolic syndrome Vol.10 Article No.11 (2018 Mar)
抄録: Background: The benefits of sodium glucose cotransporters 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus include plasma glucose control, reduction in body weight and blood pressure, and low risk of hypoglycemia, although they may also cause genitourinary infections, polyuria, or volume depletion. It is not clear whether dapagliflozin, an SGLT2 inhibitor, improves treatment satisfaction among patients in a comprehensive way despite the negative side effects. This study assessed the effect of dapagliflozin on glycosylated hemoglobin (HbA1c), body weight, and treatment satisfaction in overweight patients with type 2 diabetes mellitus treated with oral hypoglycemic agents. Methods: This multicenter, open-label, single-arm observational study included patients with type 2 diabetes mellitus administering dapagliflozin 5 or 10 mg per day for 14 weeks. Changes in treatment satisfaction were evaluated using a new version of the Oral Hypoglycemic Agent-Questionnaire (OHA-Q ver. 2) consisting of 23 items. Correlation between treatment satisfaction and HbA1c levels and body weight were analyzed using the Spearman's rank-correlation coefficient. Results: Of the 221 patients enrolled, 188 completed the study. Mean HbA1c decreased from 7.8 ± 0.7% (62.1 ± 7.5 mmol/mol) to 7.3 ± 0.8% (55.9 ± 8.7 mmol/mol) (change - 0.6 ± 0.7%, P < 0.001) and body weight decreased from 82.5 ± 14.6 to 80.7 ± 14.8 kg (change - 2.3 ± 2.8 kg, P < 0.001). OHA-Q ver. 2 was validated as well, the mean OHA-Q ver. 2 total score increased from 44.3 ± 9.4 to 46.6 ± 9.8 (best score 69, worst score 0; change 2.3 ± 6.6, P < 0.001). The change in body weight significantly correlated with the OHA-Q ver. 2 total score (Spearman's ρ = - 0.17, P = 0.035). The change in HbA1c levels significantly correlated with the satisfaction subscale score (Spearman's ρ = - 0.19, P = 0.011). Conclusions: Dapagliflozin significantly improved treatment satisfaction among patients with type 2 diabetes mellitus for 14 weeks. Body weight loss significantly correlated with treatment satisfaction.Trial registration UMIN-CTR: UMIN000016304.
内容記述: 博士(医学)・甲第694号・平成31年3月15日
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/ publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
URI: http://hdl.handle.net/10564/3542
ISSN: 17585996
DOI: http://dx.doi.org/10.1186/s13098-018-0313-x
学位授与番号: 24601A694
学位授与年月日: 2019-03-15
学位名: 博士(医学)
学位授与機関: 奈良県立医科大学
出現コレクション:2018年度

このアイテムのファイル:

ファイル 記述 サイズフォーマット
01甲694本文の要旨.pdf甲694本文の要旨1.61 MBAdobe PDF見る/開く
02甲694審査要旨.pdf甲694審査要旨426.99 kBAdobe PDF見る/開く
03甲694本文.pdf甲694本文645.01 kBAdobe PDF見る/開く

このリポジトリに保管されているアイテムは、他に指定されている場合を除き、著作権により保護されています。

 

Valid XHTML 1.0! Powered by DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - ご意見をお寄せください